Cargando…
αAzithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease without a cure and new drug strategies are urgently needed. Differences in behavior between diseased and healthy cells are well known and drug response can be different between cells isolated from IPF patients and contro...
Autores principales: | Krempaska, Kristina, Barnowski, Sandra, Gavini, Jacopo, Hobi, Nina, Ebener, Simone, Simillion, Cedric, Stokes, Andrea, Schliep, Ronja, Knudsen, Lars, Geiser, Thomas K., Funke-Chambour, Manuela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964061/ https://www.ncbi.nlm.nih.gov/pubmed/31941499 http://dx.doi.org/10.1186/s12931-020-1275-8 |
Ejemplares similares
-
Correction to: Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
por: Krempaska, Kristina, et al.
Publicado: (2020) -
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC
por: Rindlisbacher, Barbara, et al.
Publicado: (2018) -
Registries for Idiopathic Pulmonary Fibrosis: When Is It Time to Go
Global?
por: Funke-Chambour, Manuela
Publicado: (2020) -
Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis
por: Gijs, Pieter-Jan, et al.
Publicado: (2023) -
Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies
por: Schertel, Anke, et al.
Publicado: (2017)